Organovo Holdings (ONVO)
$2.12 -0.05 (-2.30%)Market Cap | 3.64M |
Revenue (ttm) | 110,000.00 |
Net Income (ttm) | -14.67M |
EPS (ttm) | N/A |
PE Ratio | 0.00 |
Forward PE | N/A |
Profit Margin | -13,336.36% |
Debt to Equity Ratio | 0.00 |
Volume | 63,600 |
Avg Vol | 804,842 |
Day's Range | N/A - N/A |
Shares Out | 1.70M |
Stochastic %K | 5% |
Beta | 1.13 |
Analysts | Strong Buy |
Price Target | $64.83 |
Latest News on ONVO

Apr 2, 2025, 8:05 AM EDT - 2 days ago
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

Mar 25, 2025, 11:25 AM EDT - 10 days ago
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

Mar 11, 2025, 7:00 AM EDT - 24 days ago
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

Mar 6, 2025, 8:05 AM EST - 4 weeks ago
Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Feb 25, 2025, 8:05 AM EST - 5 weeks ago
Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Jan 6, 2025, 8:05 AM EST - 3 months ago
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Nov 20, 2024, 8:05 AM EST - 4 months ago
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting


Jul 18, 2024, 7:55 AM EDT - 9 months ago
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

Jul 16, 2024, 8:05 AM EDT - 9 months ago
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

May 21, 2024, 8:05 AM EDT - 11 months ago
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

May 14, 2024, 11:00 AM EDT - 11 months ago
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

May 8, 2024, 8:00 PM EDT - 11 months ago
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Apr 15, 2024, 8:28 AM EDT - 1 year ago
Organovo's fatty liver disease drug meets main goal in mid-stage study



Jan 9, 2024, 8:05 AM EST - 1 year ago
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress

Dec 6, 2023, 8:05 AM EST - 1 year ago
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

Nov 13, 2023, 8:05 AM EST - 1 year ago
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

Nov 8, 2023, 8:05 AM EST - 1 year ago
Organovo Highlights FXR314 Combination Therapy Potential and Plan

Sep 8, 2023, 12:46 PM EDT - 1 year ago
Organovo to Participate in the H.C. Wainwright Global Investment Conference

Aug 23, 2023, 8:05 AM EDT - 1 year ago
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Nov 15, 2022, 8:05 AM EST - 2 years ago
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug Candidates

Sep 6, 2022, 8:20 AM EDT - 2 years ago
Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:05 AM EDT - 2 years ago
Organovo Announces Postponement of Annual Meeting of Stockholders

Mar 1, 2022, 8:05 AM EST - 3 years ago
UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Feb 23, 2022, 8:05 AM EST - 3 years ago
Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Feb 18, 2022, 4:00 PM EST - 3 years ago
Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2022, 1:00 PM EST - 3 years ago
Organovo Welcomes New Sr. Vice President of Strategy and Business Development

Feb 2, 2022, 12:00 PM EST - 3 years ago
Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents

Jan 10, 2022, 12:00 PM EST - 3 years ago
Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk

Nov 30, 2021, 8:05 AM EST - 3 years ago
Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022

Sep 17, 2021, 4:10 PM EDT - 3 years ago
Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

May 28, 2021, 9:54 AM EDT - 4 years ago
Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

Mar 2, 2021, 8:05 AM EST - 4 years ago
Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE)

Sep 3, 2020, 4:05 PM EDT - 4 years ago
Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 23, 2019, 5:05 PM EDT - 6 years ago
Organovo Holdings, Inc. (ONVO) CEO Taylor Crouch on Q4 2019 Results - Earnings Call Transcript